Amy Dedeke, MD
Rheumatology · Oklahoma City, OKNPI 1295875300
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,506 of the $5,198 with a category attached, or 67.5%. 25 manufacturers reported payments, led by Boehringer Ingelheim at 32.2% of the total.
Across 166 payments — averaging $31.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- AstraZeneca$684
- AbbVie$680
- Johnson & Johnson$503
- Amgen$404
- Novartis$239
- plus $1K from 19 others
What the payments were for
- Consulting fees$1,60031%
- Food & beverage$3,50667%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $1,674 |
| AstraZeneca(2 entities) | 21 | $684 |
| AbbVie | 39 | $680 |
| Johnson & Johnson(2 entities) | 18 | $503 |
| Amgen(2 entities) | 21 | $404 |
| Novartis | 13 | $239 |
| Novo Nordisk | 14 | $181 |
| Lilly USA, LLC | 3 | $138 |
| Aurinia Pharma U.S., Inc. | 2 | $129 |
| Sanofi | 2 | $124 |
| UCB, Inc. | 6 | $124 |
| GSK | 3 | $46 |
| Bristol Myers Squibb | 3 | $45 |
| Merck | 3 | $39 |
| Amarin Pharma, Inc. | 2 | $27 |
| Sandoz | 1 | $24 |
| Sobi, Inc | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Abbott | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Antares Pharma, Inc. | 1 | $11 |
| Dynavax Technologies Corporation | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,198 in reported general payments places this provider in the 55th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 109 | $1,055,558 |
| RinvoqUpadacitinib | 41 | $256,667 |
| Xeljanz XrTofacitinib Citrate | 41 | $239,530 |
| Enbrel SureclickEtanercept | 25 | $174,300 |
| Orencia ClickjectAbatacept | 29 | $164,276 |
| SimponiGolimumab | 11 | $67,232 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $61,399 |
| Actemra ActpenTocilizumab | 13 | $40,899 |
| Hydroxychloroquine Sulfate | 569 | $22,559 |
| Leflunomide | 193 | $7,857 |
| MethotrexateMethotrexate Sodium | 329 | $7,159 |
| Sulfasalazine | 254 | $5,084 |
| Celecoxib | 53 | $2,095 |
| Etodolac | 36 | $2,090 |
| Cevimeline Hcl | 14 | $2,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $680 | $256,66741 claims |
| Johnson & JohnsonSimponi | $503 | $67,23211 claims |
| UCB, Inc.Cimzia (2 Pack) | $124 | $61,39911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Oklahoma City
- Joan MerrillOklahoma City$864K
- Latisha HeinlenOklahoma City$675K
- Mohammad KhanOklahoma City$94K
- Cristina ArriensOklahoma City$82K
- John GoetzingerOklahoma City$18K
- Robert ArthurOklahoma City$16K
- Muhammad GillanOklahoma City$16K
- William SchnitzOklahoma City$15K
- Judith JamesOklahoma City$15K
- Amanda TitusOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.